176 related articles for article (PubMed ID: 10976008)
1. Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells.
Barillé S; Collette M; Thabard W; Bleunven C; Bataille R; Amiot M
Cytokine; 2000 Sep; 12(9):1426-9. PubMed ID: 10976008
[TBL] [Abstract][Full Text] [Related]
2. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
3. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
4. Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor.
Klouche M; Bhakdi S; Hemmes M; Rose-John S
J Immunol; 1999 Oct; 163(8):4583-9. PubMed ID: 10510402
[TBL] [Abstract][Full Text] [Related]
5. Signal through gp130 activated by soluble interleukin (IL)-6 receptor (R) and IL-6 or IL-6R/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors.
Kimura T; Wang J; Minamiguchi H; Fujiki H; Harada S; Okuda K; Kaneko H; Yokota S; Yasukawa K; Abe T; Sonoda Y
Stem Cells; 2000; 18(6):444-52. PubMed ID: 11072033
[TBL] [Abstract][Full Text] [Related]
6. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
Gaillard JP; Liautard J; Klein B; Brochier J
Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
[TBL] [Abstract][Full Text] [Related]
7. Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage.
Thabard W; Barillé S; Collette M; Harousseau JL; Rapp MJ; Bataille R; Amiot M
Clin Cancer Res; 1999 Oct; 5(10):2693-7. PubMed ID: 10537331
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase and cytokine production by bone marrow adherent cells from multiple myeloma patients.
Zdzisińska B; Walter-Croneck A; Dmoszyńska A; Kandefer-Szerszeń M
Arch Immunol Ther Exp (Warsz); 2006; 54(4):289-96. PubMed ID: 16868721
[TBL] [Abstract][Full Text] [Related]
9. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
Derenne S; Amiot M; Barillé S; Collette M; Robillard N; Berthaud P; Harousseau JL; Bataille R
J Bone Miner Res; 1999 Dec; 14(12):2048-56. PubMed ID: 10620064
[TBL] [Abstract][Full Text] [Related]
10. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression.
Suzuki M; Hashizume M; Yoshida H; Shiina M; Mihara M
Cytokine; 2010 Aug; 51(2):178-83. PubMed ID: 20403707
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
Peters M; Blinn G; Solem F; Fischer M; Meyer zum Büschenfelde KH; Rose-John S
J Immunol; 1998 Oct; 161(7):3575-81. PubMed ID: 9759879
[TBL] [Abstract][Full Text] [Related]
12. IL-6 transsignaling: the in vivo consequences.
Jones SA; Richards PJ; Scheller J; Rose-John S
J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
[TBL] [Abstract][Full Text] [Related]
14. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma.
Barillé S; Bataille R; Amiot M
Eur Cytokine Netw; 2000 Dec; 11(4):546-51. PubMed ID: 11125296
[TBL] [Abstract][Full Text] [Related]
15. The role of soluble interleukin (IL)-6 receptor in mediating the effects of IL-6 on matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 expression by gingival fibroblasts.
Irwin CR; Myrillas TT; Traynor P; Leadbetter N; Cawston TE
J Periodontol; 2002 Jul; 73(7):741-7. PubMed ID: 12146533
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.
Lasfar A; Wietzerbin J; Billard C
Eur J Immunol; 1994 Jan; 24(1):124-30. PubMed ID: 8020547
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes.
Paysant J; Blanqué R; Vasse M; Soria C; Soria J; Gardner CR
Cytokine; 2000 Jun; 12(6):774-9. PubMed ID: 10843763
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage.
Taguchi Y; Yamamoto M; Yamate T; Lin SC; Mocharla H; DeTogni P; Nakayama N; Boyce BF; Abe E; Manolagas SC
Proc Assoc Am Physicians; 1998; 110(6):559-74. PubMed ID: 9824538
[TBL] [Abstract][Full Text] [Related]
19. [Soluble IL-6 receptors].
Jabłońska E
Postepy Hig Med Dosw; 1998; 52(2):133-8. PubMed ID: 9640977
[TBL] [Abstract][Full Text] [Related]
20. The soluble IL-6 receptors: serum levels and biological function.
Montero-Julian FA
Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):583-97. PubMed ID: 11502067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
